Granted by the United States Patent and Trademark Office (USPTO), the patent covers a technique that uses drug-loaded liposomes, cancer-targeting antibodies and ultrasound to direct chemotherapy towards specific cancer cells.

UAE – American University of Sharjah (AUS) has secured a third US patent for a breast cancer drug delivery method that combines antibody-targeted capsules with ultrasound to release chemotherapy at tumour sites, expanding its research into more targeted cancer treatments.
Granted by the United States Patent and Trademark Office (USPTO), the patent covers a technique that uses drug-loaded liposomes, cancer-targeting antibodies and ultrasound to direct chemotherapy towards specific cancer cells.
The research team is led by Dr. Ghaleb Husseini, AUS Associate Vice Chancellor for Research and Professor of Chemical and Biological Engineering.
Other contributors include Dr. Mohammad Al-Sayah, Professor of Biology, Chemistry and Environmental Sciences, and Amal Elsadig, a 2018 AUS Master of Science in Chemical Engineering graduate who is pursuing a PhD in chemical engineering at Khalifa University.
Expanding the scope of targeted drug delivery
The method uses liposomes, microscopic capsules made from fatty substances similar to those found in cell membranes.
These capsules carry chemotherapy drugs and have antibodies attached to their surfaces.
The antibodies recognize specific proteins on cancer cells, helping direct the drug carriers towards the tumour.
Once the capsules reach the targeted area, ultrasound waves disrupt their structure and trigger the release of the chemotherapy.
The latest patent introduces cetuximab, an antibody that targets the epidermal growth factor receptor (EGFR), a protein expressed by some breast cancer cells.
Earlier patents covered trastuzumab, also known as Herceptin, which targets the HER2 protein.
The addition of cetuximab extends the approach to another potential target, particularly in some triple-negative breast cancers.
These tumours lack estrogen and progesterone receptors and HER2, although some express high levels of EGFR.
“This patent extends our research to capsules that use cetuximab to recognize EGFR on some breast cancer cells. The antibody helps direct the capsules towards the tumour, while ultrasound triggers the release of chemotherapy at the targeted area,” said Dr. Husseini.
Further testing needed before clinical development
The patent forms part of an invention family first filed in 2017.
AUS received its first US patent in 2020 for Herceptin-targeted capsules, followed by a second in 2024 covering additional ultrasound frequencies and power levels. The latest patent adds the cetuximab-based approach.
However, the new capsules have not yet undergone testing.
Dr. Al-Sayah noted that EGFR expression in some triple-negative breast cancers makes it a relevant marker for investigating targeted drug delivery, but further studies are needed to establish the method’s potential.
Animal studies of the Herceptin-targeted capsules are ongoing to assess their safety and effectiveness. The research team plans to investigate the cetuximab-based formulation after completing this work.
Before the technology can enter human trials, it will require additional preclinical research, pharmaceutical-grade manufacturing, formal safety assessments and regulatory approval.
The animal studies also involve AUS postdoctoral research fellows Dr. Remya Radha and Dr. Vinod Paul, alongside Dr. Shabana Anjum of Mohammed Bin Rashid University of Medicine and Health Sciences.
“As an AUS alumna and co-inventor, I am proud to see this work recognized with a patent. Further testing will help determine whether the method can progress towards future development,” said Elsadig.
The research was conducted by AUS’ Ultrasound in Cancer Research Group, with contributions from undergraduate and graduate students and postdoctoral fellows.
Funding has come from university research grants, cancer research foundations, government innovation programmes and other institutional partners, including the Al Jalila Foundation, Friends of Cancer Patients and the Abu Dhabi Department of Economic Development’s Takamul Program.
The development adds to AUS’ intellectual property portfolio and highlights the role of university-led research in developing targeted drug delivery technologies.
For the pharmaceutical and biotechnology sectors, such approaches offer an area for further investigation into improving drug localisation and potentially limiting exposure of healthy tissues to chemotherapy.
Be the first to leave a comment